Kayla V. Sprague

FDA investigator

Appears on 17 documents from 2020 to 2026, mostly at sites in Florida. Most often cites insanitary conditions (FDCA 501(a)(2)(A)).

17
Documents on file
5.4
Observations per 483
2020
First seen
2026
Most recent

What they cite most

From 91 observations

Activity by year

2020: 2, 2021: 2, 2022: 3, 2023: 2, 2024: 3, 2025: 2, 2026: 3

Where

Florida 15 · Arkansas 1 · North Carolina 1

Is Kayla V. Sprague coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

17 documents, newest first
FirmOpen
483 Fujifilm Diosynth Biotechnologies USA Inc.Mar 27, 2026 · Research Triangle Park, North Carolina
483 CoreRX Inc. DBA Bend BioscienceFeb 26, 2026 · Clearwater, Florida
483 Hit Promotional Products Inc.Jan 28, 2026 · Saint Petersburg, Florida
483 LEESAR, INCMay 9, 2025 · Fort Myers, Florida
483 Epic Laboratories, LLCApr 2, 2025 · Tampa, Florida
483 BEO Pharma Inc. dba BEO PharmaceuticalsNov 4, 2024 · Brooksville, Florida
483 Belcher Pharmaceuticals, LLCAug 16, 2024 · Largo, Florida

About this profile

What does Kayla V. Sprague inspect?

Kayla V. Sprague appears on 17 documents on file covering 15 sites, mostly in Florida.

What do they cite most often?

FDCA 501(a)(2)(A) (insanitary conditions), followed by 21 CFR 211.22 and 21 CFR 211.192.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Kayla V. Sprague is dated Mar 27, 2026.